Q4 2022 Results slide image

Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology Biosimilars 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 104 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation